Vesico-Ureteral Reflux Clinical Trial
— ceVUSOfficial title:
Contrast Enhanced Voiding Urosonography (ceVUS) With the Intravesical Administration of the Ultrasound Contrast Agent OPTISON TM (Trademark) for Vesicoureteral Reflux Detection and Urethral Imaging in Children.
Verified date | October 2018 |
Source | Children's Hospital of Philadelphia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this clinical trial the investigators aim to evaluate the diagnostic feasibility and safety of ceVUS with the intravesical use of OPTISON for vesicoureteral reflux detection and urethral imaging in children.
Status | Completed |
Enrollment | 31 |
Est. completion date | March 2017 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 18 Years |
Eligibility |
Inclusion criteria: 1. Children 2-18 years (first age cohort). 2. Children 0-18 years (second age cohort). 3. Referred to the Children's Hospital of Philadelphia (CHOP) for the performance of the clinically indicated Voiding Cystourethrography (VCUG) examination. 4. Parental/guardian permission (informed consent) and if appropriate, child's assent for additional performance of contrast enhanced Voiding Urosonography (ceVUS) examination. Exclusion criteria: 1. Hypersensitivity to perflutren, blood, blood products or albumin. 2. Children requiring sedation for VCUG or ceVUS examinations. 3. Parents/guardians or subjects who, in the opinion of the principal investigator, may be non-compliant with study schedules or procedures. |
Country | Name | City | State |
---|---|---|---|
United States | Department of Radiology, the Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Kassa Darge |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Pelvic-ureter-units (PUUs) Detected With Vesicoureteral Reflux by Contrast Enhanced Voiding Urosonography (ceVUS) and by Voiding Cystourethrography (VCUG). | Presence or absence of vesicoureteral reflux identified by ceVUS and VCUG in each pelvic-ureter-unit (PUU) of each participant. PUU is an anatomic term that is used to describe the part of the urinary tract consisting of the renal calyces, pelvis and ureter. Grading the severity of reflux detected by ceVUS and VCUG. Grade 0: absence of reflux. If reflux is present, a 5 grade scale (grades I-V) is used to evaluate its severity. Grade I: reflux in the ureter, grade II: reflux up to the renal pelvis, grade III: reflux up to the renal pelvis with mild dilation of the ureter and pelvicalyceal system, grade IV reflux up to the renal pelvis with moderate dilation but preserved papillary impressions, grade V: reflux up to the renal pelvis with severe dilation and loss of papillary impressions. Higher grades of reflux are associated with increased risk of urinary tract infection. Imaging of the urethra during voiding (urethra visualized or not) and urethra pathology detection. |
10-15 minutes. | |
Primary | Number of Participants With Adverse Events Following Contrast Enhanced Voiding Urosonography (ceVUS) With OPTISON and Voiding Cystourethrography (VCUG). | The overall safety and tolerability of ceVUS with OPTISON was assessed before, during and immediately after each ceVUS and VCUG examinations, and in follow-up telephone interviews. Assessments included: evaluation of body systems for signs of generalized hypersensitivity, allergic or anaphylactoid reactions monitoring of heart rate and pulse oxygen saturation telephone questionnaire-based interview of parents/guardians and children 48 hours after the examinations for delayed adverse events. The severity of any possible adverse event was classified as mild, moderate or serious and the onset of symptoms was categorized as acute, subacute or delayed according to the World Health Organization (WHO) classifications. In addition, the adverse event was classified as anticipated if it was expected given the study related procedures or unanticipated if the subject was exposed to greater risk than previously known or recognized. |
Within 1 hour and up to 2 days after ceVUS and VCUG examinations completion. | |
Secondary | Compare the Diagnostic Accuracy of Contrast Enhanced Voiding Urosonography (ceVUS) With Voiding CystoUrethroGraphy (VCUG) for Vesicoureteral Reflux Detection and Urethral Imaging in Children. | The diagnostic accuracy of ceVUS will be assessed by evaluation of the true positive, true negative, false positive and false negative cases of reflux and urethral imaging findings detected by ceVUS and VCUG examinations. | 10-15 minutes. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02271035 -
A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children
|
Phase 4 | |
Not yet recruiting |
NCT03653702 -
Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)
|
Phase 1 | |
Completed |
NCT04798443 -
Endoscopic Injection of Dextranomer/Hyaluronic Acid Versus Ureteral Reimplantation In Treatment of Vesicoureteral Reflux
|
N/A | |
Completed |
NCT05864131 -
Effects of Parental Holding on Pain Response in Young Children During Cystometry
|
N/A | |
Completed |
NCT01297673 -
Reflux in Spinal Cord Injury Patients With Neurogenic Lower Urinary Tract Dysfunction
|
N/A | |
Recruiting |
NCT00367159 -
Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children
|
Phase 3 | |
Withdrawn |
NCT02986477 -
Clinical Applications of Contrast-Enhanced Ultrasonography in Pediatric Population - Intravesicle Administration
|
N/A | |
Active, not recruiting |
NCT04251988 -
VR to Reduce Pain and Anxiety During GU Scans
|
N/A |